These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27136919)

  • 21. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis.
    Albert DA
    J Clin Rheumatol; 2015 Dec; 21(8):398-404. PubMed ID: 26226612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life.
    Benucci M; Saviola G; Baiardi P; Manfredi M
    Rheumatol Int; 2011 Nov; 31(11):1465-9. PubMed ID: 20473760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.
    Bredemeier M; Campos GG; de Oliveira FK
    Clin Rheumatol; 2015 Oct; 34(10):1801-5. PubMed ID: 26070536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.
    Soini E; Asseburg C; Taiha M; Puolakka K; Purcaru O; Luosujärvi R
    Adv Ther; 2017 Oct; 34(10):2316-2332. PubMed ID: 28975568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France.
    Fagnani F; Pham T; Claudepierre P; Berenbaum F; De Chalus T; Saadoun C; Joubert JM; Fautrel B
    J Med Econ; 2016 Aug; 19(8):812-21. PubMed ID: 27065315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis.
    Benucci M; Iannazzo S; Zaniolo O; Sabadini L
    Clin Exp Rheumatol; 2010; 28(5):722-7. PubMed ID: 20883636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2004; 22(16):1071-95. PubMed ID: 15524495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.